title: A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior.
abstract: METHODS
  We describe a 44-year-old woman with a primary retroperitoneal serous cystadenocarcinoma as the fourth report in the world literature. A contrast-enhanced computed tomographic scan of the abdomen demonstrated a mass with enhanced solid mural nodules and septa in the left retroperitoneum. Serum CA19-9 was elevated at 181 U/ml. The patient underwent a complete resection of the retroperitoneal tumor with a partial resection of the psoas major muscle and its fascia. Pathological examination showed a well-differentiated papillary serous cystadenocarcinoma of ovarian type and locoregional lymph node metastases. Seven months after surgery, the patient developed a pelvic recurrence, and underwent a total hysterectomy, a left salpingo-oophorectomy and a resection of the metastatic mesenteric mass. Two months after the second surgery, serum CA19-9 and CA125 increased to 1,114 U/ml and 218 U/ml, respectively. A solitary liver metastasis was confirmed on a computed tomographic scan. The patient is now being treated with weekly docetaxel and carboplatin.
  
  
  CONCLUSIONS
  The present case illustrates the clinically aggressive nature of a primary retroperitoneal serous cystadenocarcinoma.
authors.affiliation: Department of Internal Medicine, Kaku Clinic, Kobe, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kaku
authors.forename: N
authors.initials: N
authors.lastname: Ohara
authors.forename: Y
authors.initials: Y
authors.lastname: Seima
authors.forename: K
authors.initials: K
authors.lastname: Imanishi
authors.forename: N
authors.initials: N
authors.lastname: Tomura
authors.forename: A
authors.initials: A
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Yamasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Hirata
authors.forename: S
authors.initials: S
authors.lastname: Murao
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D018394:CA-125 Antigen / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D016190:Carboplatin / Q000627:therapeutic use; D018284:Cystadenocarcinoma, Serous / Q000175:diagnosis* / Q000473:pathology / Q000556:secondary / Q000601:surgery; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy / Q000556:secondary; D008279:Magnetic Resonance Imaging; D008643:Mesentery; D009364:Neoplasm Recurrence, Local / Q000601:surgery; D010386:Pelvic Neoplasms / Q000556:secondary; D012186:Retroperitoneal Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery; D043823:Taxoids / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin